Objective To investigate the effect of tirofiban combined with dual antiplatelet therapy on ventricular remodeling after percutaneous coronary intervention (PCI) in patients with acute myocardial infarction (AMI). Methods The data of 86 AMI patients who completed PCI treatment in the General Hospital of Pingmei Shenma Medical Group from March 2021 to March 2023 were retrospectively collected. According to different treatment regimens after PCI, the patients were divided into the control group (43 cases, receiving conventional dual antiplatelet therapy) and the observation group (43 cases, receiving conventional dual antiplatelet plus tirofiban therapy). The cardiac function indicators [left ventricular end-systolic dimension (LVESD), left ventricular ejection fraction(LVEF), and left ventricular end-diastolic dimension (LVEDD)], ventricular remodeling indicators [inter ventricular septum thickness (IVST), left ventricular mass index (LVMI)], and myocardial injury markers [creatine kinase isoenzyme MB (CK-MB), cardiac troponin I (cTnI)] level were compared between the two groups. Record the occurrence of adverse reactions during the treatment period. Results At 48 hours of treatment, the LVEDD and LVESD levels in the observation group were (58.30±6.15) mm and (41.53±4.39) mm, which were lower than those in the control group (62.47±6.02) mm and (44.14±4.34) mm, respectively. The LVEF level was (40.08±5.09)%, which was higher than that in the control group (36.87±5.53)% (P<0.05). At 48 hours of treatment, the IVST and LVMI of the observation group were (8.79±0.34) mm and (118.08±4.09) g/m2, which were lower than those of the control group (9.23±0.39) mm and (123.86±4.53) g/m2 (P<0.05). At 48 hours of treatment, the CK-MB and cTnI levels in the observation group were (13.85±2.81) ng/mL and (0.88±0.12) μ g/L, which were lower than those in the control group (17.89±3.79) ng/mL and (1.16±0.25) μ g/L (P<0.05). During the treatment period, the total incidence of adverse reactions in the observation group was 11.64%, and there was no statistical significant difference compared to 16.29% of the control group(P>0.05). Conclusion The use of tirofiban combined with dual antiplatelet therapy in AMI patients after PCI can improve their cardiac function indicators and ventricular remodeling indicators, reduce their levels of myocardial injury markers, and does not increase adverse reactions.